Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Regulatory affairs and submissions services

SubmarketREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Regulatory affairs and submissions services

Advice, documentation, testing and submission support for regulatory approval and market authorisation across jurisdictions, including quality-system and technical-file preparation.

Market size
$3.2B
$3.2B ($2.1B–$4.6B) · 2025 · Triangulated
Growth
+6.5%
$8.1B by 2031
Attractiveness
75 /100
for B2B sellers
Evidence
Medium confidence
6 sources · Triangulated
Level
Submarket
Segmented by
Product or service
Buyers
Medical-device, diagnostic, digital-health and life-science vendors
Buying centre
Regulatory affairs, quality, clinical affairs, legal, executive leadership
Maturity
Growth
Structure
Fragmented
Buying triggers
  • MDR transition deadlines for legacy devices
  • FDA 510(k)/PMA submissions for new devices and software as a medical device
  • IVDR certification for in-vitro diagnostics
  • New market entry into EU, US, Japan, China
Pains
  • Siloed, manual submission preparation is resource-intensive [4]
  • Incomplete data causing audit findings and products shipped where they should not be [4]
  • Lack of visibility into regulatory workload and future needs [4]
  • Schedule risk from jurisdiction-by-jurisdiction rule divergence
Scores (1–5)
Pain intensity4
Purchasing power3
Reachability4
Growth4
Growth drivers
  • EU MDR/IVDR re-certification and new technical documentation requirements [2]
  • Multi-country registration programmes for commercial launch
  • Regulatory data quality and traceability expectations rising [4]
  • Outsourcing of writing, publishing and submission logistics [5][6]
Headwinds
  • Large medtech firms building in-house regulatory affairs centres [4]
  • Commoditised document-preparation pricing
  • Device company budget pressure from slower hospital capital spending
Trends
  • Digital regulatory information management (RIM) and e-submission tooling integration [4]
  • Consolidation of small consultancies into specialist regulatory houses
  • Shift from project-based to retained/managed-service contracts
  • Growth of regulatory intelligence subscriptions alongside project work

Niches 4

Split by customer type.

Niche80/100

Pharma and biopharma regulatory outsourcing

Pharmaceutical and biotechnology vendors buying outsourced regulatory submissions, regulatory consulting, writing and publishing, product registration and related approval support

$8.9B
Pharmaceutical and biotechnology companies
Medium confidenceOpen
Niche80/100

Medtech regulatory submission and market-access support

Medical-device and diagnostic vendors outsourcing regulatory-affairs advice, documentation, testing coordination and submission support for product approval and market authorisatio

$4.6B
Medical-device and diagnostic manufacturers
Medium confidenceOpen

How this was sized

$3.2B ($2.1B–$4.6B) · 2025 · Triangulated

Device regulatory affairs outsourcing is USD 2.1B in 2024 rising to USD 8.1B by 2031 at 6-7% [2]; the broader regulatory affairs outsourcing market is USD 8.1B (2025) to USD 15.7B (2034) at 7.6% [9], USD 8.20B (2025) [6], USD 8.40B (2025) [5], USD 8.95B (2025) [10]. Regulatory consulting is the largest service type at 40% of the outsourcing market [8]. Medtech/diagnostics share of the broader market is taken at roughly 35-40% (device segment USD 2.1B [2] plus diagnostics and digital-health vendors), giving a USD 2.1-4.6B range and a USD 3.2B midpoint for 2025. Forecast anchored on the USD 8.1B 2031 device figure [2].

Alongside it in Clinical and regulatory support services

// Sell into Regulatory affairs and submissions services

AOS finds the biggest accounts in this submarket with a reason to talk now, maps their buying centre and prepares the outreach for your approval.